Per Malmström

Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity

Lao H. Saal, Peter A. Johansson, Karolina Holm et al. · Proceedings of the National Academy of Sciences · 2007 · 521 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial

Jonas Bergh, Tom Wiklund, Björn Erikstein et al. · The Lancet · 2000 · 342 citations

Medicine, Oncology, Pharmacology +17

Topoisomerase IIα Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in <i>HER-2/neu</i>–Amplified Breast Cancer: Scandinavian Breast Group Trial 9401

Minna Tanner, Jorma Isola, Tom Wiklund et al. · Journal of Clinical Oncology · 2006 · 255 citations · Full text

Medicine, Oncology, Pharmacology +16

Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics

Göran Jönsson, Johan Staaf, Johan Vallon‐Christersson et al. · Breast Cancer Research · 2010 · 194 citations · Full text

Life Sciences, Molecular Genetics, Oncology +16

Estrogen Receptor β Expression Is Associated with Tamoxifen Response in ERα-Negative Breast Carcinoma

Sofia K. Gruvberger-Saal, Pär‐Ola Bendahl, Lao H. Saal et al. · Clinical Cancer Research · 2007 · 179 citations

Medicine, Cancer Biology, Oncology +16